Separately, Zacks Investment Research raised NicOx from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, July 23rd.
NicOx stock traded down $0.07 during mid-day trading on Thursday, hitting $5.12. The company’s stock had a trading volume of 3,573 shares, compared to its average volume of 3,695. The company has a 50 day simple moving average of $5.56. NicOx has a one year low of $5.10 and a one year high of $9.68.
Nicox SA, an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The company's product pipeline includes VyzultaTM, an intraocular pressure-lowering treatment; and NCX 470, a nitric oxide (NO)-donating candidate to treat glaucoma, as well as stand-alone NO donors for specific applications in ophthalmic diseases.
See Also: Rule of 72
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NicOx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NicOx and related companies with MarketBeat.com's FREE daily email newsletter.